Joseph P Sanderson

List of Publications by Year
in descending order

21 papers	**1,019** citations	759233 **12** h-index	752698 **20** g-index
21 all docs	**21** docs citations	**21** times ranked	**1440** citing authors

#	Article	IF	Citations
1	Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nature Immunology, 2011, 12, 1202-1211.	14.5	275
2	Activation of T cells by carbamazepine and carbamazepine metabolites. Journal of Allergy and Clinical Immunology, 2006, 118, 233-241.	2.9	121
3	Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling. Journal of Immunology, 2007, 178, 5533-5542.	0.8	111
4	Role of bioactivation in drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E55-E64.	4.4	60
5	Innate-Like Control of Human iNKT Cell Autoreactivity via the Hypervariable CDR3Î² Loop. PLoS Biology, 2010, 8, e1000402.	5.6	60
6	Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. OncoImmunology, 2020, 9, 1682381.	4.6	54
7	An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. PLoS ONE, 2018, 13, e0205491.	2.5	53
8	Tuning Tâ€Cell Receptor Affinity to Optimize Clinical Riskâ€Benefit When Targeting Alphaâ€Fetoproteinâ€"Positive Liver Cancer. Hepatology, 2019, 69, 2061-2075.	7.3	52
9	Î²-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2013, 26, 963-975.	3.3	50
10	Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate. OncoImmunology, 2019, 8, e1532759.	4.6	44
11	Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid Arthritis. Journal of Immunology, 2015, 195, 5582-5591.	0.8	26
12	<scp>CD</scp>1d protein structure determines speciesâ€selective antigenicity of isoglobotrihexosylceramide (i<scp>G</scp>b3) to invariant <scp>NKT</scp> cells. European Journal of Immunology, 2013, 43, 815-825.	2.9	24
13	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
14	Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. Journal of Allergy and Clinical Immunology, 2011, 128, 680-683.e5.	2.9	12
15	T-cell populations in chronic pancreatitis. Pancreatology, 2015, 15, 311-312.	1.1	12
16	Natural variations at position 93 of the invariant VÎ±24â€JÎ±18 Î± chain of human iNKTâ€cell TCRs strongly impact on CD1d binding. European Journal of Immunology, 2012, 42, 248-255.	2.9	11
17	Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-Î². Journal of Immunology, 2022, 208, 169-180.	0.8	10
18	The Clonal Invariant NKT Cell Repertoire in People with Type 1 Diabetes Is Characterized by a Loss of Clones Expressing High-Affinity TCRs. Journal of Immunology, 2017, 198, 1452-1459.	0.8	9

#	Article	IF	Citations
19	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Frontiers in Oncology, 2022, 12, 818679.	2.8	8
20	Nonenzymatic Formation of a Novel Hydroxylated Sulfamethoxazole Derivative in Human Liver Microsomes: Implications for Bioanalysis of Sulfamethoxazole Metabolites. Drug Metabolism and Disposition, 2008, 36, 2424-2428.	3.3	4
21	Trimethoprim Stimulates T-Cells through Metabolism-Dependent and -Independent Pathways. Chemical Research in Toxicology, 2011, 24, 791-793.	3.3	4